What is Intelligencia AI?
Intelligencia AI operates at the intersection of artificial intelligence and pharmaceutical R&D. The company provides a sophisticated platform designed to minimize the risk of drug development by enabling executives to assess clinical programs with unprecedented precision. By transforming how R&D and Business Development leaders evaluate their internal pipelines and external opportunities, Intelligencia AI facilitates more informed, data-driven decision-making. Its market position is defined by its ability to convert complex clinical data into actionable insights, effectively reducing the uncertainty that often plagues high-stakes pharmaceutical investments.
How much funding has Intelligencia AI raised?
Intelligencia AI has raised a total of $12M across 1 funding round:
Series A
$12M
Series A (2021): $12M with participation from Mtip, Big Pi Ventures, and Synetro Group
Key Investors in Intelligencia AI
Mtip
MTIP is a Swiss growth and buyout firm that specializes in acquiring and investing in profitable, high-growth healthcare software companies with SaaS B2B characteristics.
Big Pi Ventures
Big Pi Ventures is a multi-stage technology investment platform that supports extraordinary entrepreneurs, managing significant assets to assist high-growth tech businesses across various cycles.
Synetro Group
Synetro Group is a Chicago-based private investment and strategic advisory firm focusing on technology, business services, and health tech sectors through active engagement.
What's next for Intelligencia AI?
With this major enterprise-level funding, Intelligencia AI is poised to scale its operations and expand its footprint in the global healthcare software market. The strategic focus will likely shift toward enhancing the predictive capabilities of its AI models and broadening its service offerings to support a wider array of clinical development stakeholders. As the firm continues to integrate its solutions into the workflows of major pharmaceutical players, the focus will remain on driving operational efficiency and fostering long-term value creation. The company is expected to leverage its recent capital to solidify its leadership position, ensuring that its technology remains the gold standard for risk assessment in the rapidly evolving drug development ecosystem.
See full Intelligencia AI company page
